Optimal Antithrombotic Strategies in Cardiogenic Shock

Overview

Journal J Clin Med

Specialty General Medicine

Date 2024 Jan 11

PMID 38202284

Authors

Michal Droppa

Tobias Geisler

Affiliations

Soon will be listed here.

Abstract

Cardiogenic shock (CS) represents a critical condition with a high mortality rate. The most common cause of CS is coronary artery disease, and patients typically present with myocardial infarction, necessitating immediate treatment through percutaneous coronary intervention (PCI) and often requiring mechanical circulatory support. CS is associated with a prothrombotic situation, while on the other hand, there is often a significant risk of bleeding. This dual challenge complicates the selection of an optimal antithrombotic strategy. The choice of antithrombotic agents must be personalized, taking into consideration all relevant conditions. Repeated risk assessment, therapeutic monitoring, and adjusting antithrombotic therapy are mandatory in these patients. This review article aims to provide an overview of the current evidence and practical guidance on antithrombotic strategies in the context of CS.

References

Joffre J, Varenne O, Bougouin W, Rosencher J, Mira J, Cariou A . Stent thrombosis: an increased adverse event after angioplasty following resuscitated cardiac arrest. Resuscitation. 2014; 85(6):769-73. DOI: 10.1016/j.resuscitation.2014.02.013. View

Shah N, Chaudhary R, Mehta K, Agarwal V, Garg J, Freudenberger R . Therapeutic Hypothermia and Stent Thrombosis: A Nationwide Analysis. JACC Cardiovasc Interv. 2016; 9(17):1801-11. DOI: 10.1016/j.jcin.2016.06.052. View

Boriani G, Fauchier L, Aguinaga L, Beattie J, Blomstrom Lundqvist C, Cohen A . European Heart Rhythm Association (EHRA) consensus document on management of arrhythmias and cardiac electronic devices in the critically ill and post-surgery patient, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society.... Europace. 2018; 21(1):7-8. DOI: 10.1093/europace/euy110. View

Karathanos A, Lin Y, Dannenberg L, Parco C, Schulze V, Brockmeyer M . Routine Glycoprotein IIb/IIIa Inhibitor Therapy in ST-Segment Elevation Myocardial Infarction: A Meta-analysis. Can J Cardiol. 2019; 35(11):1576-1588. DOI: 10.1016/j.cjca.2019.05.003. View

Steg P, Bhatt D, Hamm C, Stone G, Gibson C, Mahaffey K . Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. Lancet. 2013; 382(9909):1981-92. DOI: 10.1016/S0140-6736(13)61615-3. View

Gernhofer Y, Banks D, Golts E, Pretorius V . Novel Use of Cangrelor With Heparin During Cardiopulmonary Bypass in Patients With Heparin-Induced Thrombocytopenia Who Require Cardiovascular Surgery: A Case Series. Semin Thorac Cardiovasc Surg. 2019; 32(4):763-769. DOI: 10.1053/j.semtcvs.2019.10.002. View

Lip G, Collet J, Haude M, Byrne R, Chung E, Fauchier L . 2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the.... Europace. 2018; 21(2):192-193. DOI: 10.1093/europace/euy174. View

Gouffran G, Rosencher J, Bougouin W, Jakamy R, Joffre J, Lamhaut L . Stent thrombosis after primary percutaneous coronary intervention in comatose survivors of out-of-hospital cardiac arrest: Are the new P2Y12 inhibitors really more effective than clopidogrel?. Resuscitation. 2015; 98:73-8. DOI: 10.1016/j.resuscitation.2015.11.006. View

Vandenbriele C, Arachchillage D, Frederiks P, Giustino G, Gorog D, Gramegna M . Anticoagulation for Percutaneous Ventricular Assist Device-Supported Cardiogenic Shock: JACC Review Topic of the Week. J Am Coll Cardiol. 2022; 79(19):1949-1962. DOI: 10.1016/j.jacc.2022.02.052. View

10.

Gargiulo G, Esposito G, Avvedimento M, Nagler M, Minuz P, Campo G . Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment-Elevation Myocardial Infarction: Primary Results of the FABOLUS-FASTER Trial. Circulation. 2020; 142(5):441-454. PMC: 7392586. DOI: 10.1161/CIRCULATIONAHA.120.046928. View

11.

Liu C, Mao Z, Kang H, Hu J, Zhou F . Regional citrate versus heparin anticoagulation for continuous renal replacement therapy in critically ill patients: a meta-analysis with trial sequential analysis of randomized controlled trials. Crit Care. 2016; 20(1):144. PMC: 4866420. DOI: 10.1186/s13054-016-1299-0. View

12.

Harrington R, Stone G, McNulty S, White H, Lincoff A, Gibson C . Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med. 2009; 361(24):2318-29. DOI: 10.1056/NEJMoa0908628. View

13.

Thiele H, Akin I, Sandri M, Fuernau G, de Waha S, Meyer-Saraei R . PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock. N Engl J Med. 2017; 377(25):2419-2432. DOI: 10.1056/NEJMoa1710261. View

14.

. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med. 1998; 339(7):436-43. DOI: 10.1056/NEJM199808133390704. View

15.

Kubica J, Adamski P, Ostrowska M, Sikora J, Kubica J, Sroka W . Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. Eur Heart J. 2015; 37(3):245-52. PMC: 4712351. DOI: 10.1093/eurheartj/ehv547. View

16.

Pollack Jr C, Kurz M, Hayward N . EP-7041, a Factor XIa Inhibitor as a Potential Antithrombotic Strategy in Extracorporeal Membrane Oxygenation: A Brief Report. Crit Care Explor. 2020; 2(9):e0196. PMC: 7498136. DOI: 10.1097/CCE.0000000000000196. View

17.

Baldetti L, Nardelli P, Ajello S, Melisurgo G, Calabro M, Pieri M . Anti-thrombotic Therapy With Cangrelor and Bivalirudin in Venoarterial Extracorporeal Membrane Oxygenation Patients Undergoing Percutaneous Coronary Intervention: A Single-Center Experience. ASAIO J. 2022; 69(7):e346-e350. DOI: 10.1097/MAT.0000000000001871. View

18.

Moudgil R, Al-Turbak H, Osborne C, Hibbert B, So D, Le May M . Superiority of ticagrelor over clopidogrel in patients after cardiac arrest undergoing therapeutic hypothermia. Can J Cardiol. 2014; 30(11):1396-9. DOI: 10.1016/j.cjca.2014.07.745. View

19.

Vidal S, Richebe P, Barandon L, Calderon J, Tafer N, Pouquet O . Evaluation of continuous veno-venous hemofiltration for the treatment of cardiogenic shock in conjunction with acute renal failure after cardiac surgery. Eur J Cardiothorac Surg. 2009; 36(3):572-9. DOI: 10.1016/j.ejcts.2009.04.018. View

20.

Erdoes G, Koster A, Levy J . Viscoelastic Coagulation Testing: Use and Current Limitations in Perioperative Decision-making. Anesthesiology. 2021; 135(2):342-349. DOI: 10.1097/ALN.0000000000003814. View